Caring Brands (NASDAQ:CABR) Posts Quarterly Earnings Results

Caring Brands (NASDAQ:CABR) released its quarterly earnings data on Tuesday. The company reported ($0.27) earnings per share for the quarter, Zacks reports.

Caring Brands Price Performance

Shares of CABR traded up $0.16 during midday trading on Tuesday, reaching $1.07. The stock had a trading volume of 173,039 shares, compared to its average volume of 123,815. The firm has a 50 day moving average of $1.03. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35. The firm has a market cap of $9.57 million and a P/E ratio of -2.89. The company has a quick ratio of 13.09, a current ratio of 13.16 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new stake in shares of Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent SEC filing.

Wall Street Analyst Weigh In

Separately, Weiss Ratings assumed coverage on shares of Caring Brands in a research note on Monday, January 26th. They issued a “sell (e)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Caring Brands has an average rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.